---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-044563"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:30:41.223382+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech Q3 net loss $213.7M; closes Sanofi TCE licensing deal, appoints new CFO

## Summary
- Net loss $213.7M ($1.56 per share) vs $163.4M ($1.22) in Q3 2023; revenue $2.4M, down from $2.6M.
- Closed exclusive worldwide license with Sanofi for three dual-masked T-cell engagers; paid $103.7M upfront.
- Workforce reduction of ~25% (140 employees) as part of restructuring; expects ~435 employees by year-end.
- Jason O'Byrne appointed as CFO effective Oct 2, 2024; brings 20+ years finance experience.
- R&D expenses surged to $195.2M (including $102.8M Sanofi upfront IPR&D); SG&A down to $25.7M.

## SEC filing metadata
- accession: 0001628280-24-044563
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828024044563/0001628280-24-044563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828024044563/vir-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-044563
- JSON: https://secwatch.observer/filing/0001628280-24-044563.json
- Plain text: https://secwatch.observer/filing/0001628280-24-044563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.